Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-center, one-arm, prospective phase II clinical study of the efficacy and safety of sintilimab combined with anlotinib in the treatment of persistent, recurrent, and metastatic cervical cancer

Next Previous
Trial Profile

Single-center, one-arm, prospective phase II clinical study of the efficacy and safety of sintilimab combined with anlotinib in the treatment of persistent, recurrent, and metastatic cervical cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Catequentinib (Primary) ; Sintilimab (Primary)
  • Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
  • Focus Therapeutic Use

Most Recent Events

  • 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 04 Jul 2022 Status changed from recruiting to active, no longer recruiting.
  • 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top